Following on from information provided to NICE by the company in October 2020 the appraisal of Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1381
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 December 2022 | Discontinued. Following on from information provided to NICE by the company in October 2020 the appraisal of Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 23 October 2020 | Note added to the project documents |
| 23 October 2020 | Suspended. Topic is suspended |
| 22 June 2020 | Note added to the project documents |
| 30 September 2019 | Note added to the project documents |
| 27 September 2019 | In progress. Referred 13/02/2018 |
For further information on our processes and methods, please see our CHTE processes and methods manual